Highlights

  • Racura Oncology has entered into an Underwriting agreement covering remaining unexercised $1.25 Piggyback Options.
  • More than 18.3 million of the 20.1 million Piggyback Options have already been exercised.
  • The exercised options have generated approximately $22.88 million for the company so far.
  • Full conversion of all options would increase total proceeds to approximately $25.2 million.
  • The underwriting agreement covers up to 1,838,524 remaining options.
  • Funds are expected to support clinical programs across AML, lung cancer and anthracycline cardioprotection.

Racura Oncology Ltd (ASX:RAC) has entered into an underwriting agreement covering the remaining unexercised Piggyback Options ahead of their scheduled expiry, with the arrangement expected to provide additional funding certainty for the company’s clinical development programs.

The company announced that existing Shareholder Dr AJ Robinson has agreed to underwrite any remaining $1.25 Piggyback Options (ASX:RACAAA) that remain unexercised at the expiry deadline of 5pm on 29 May 2026.

Racura stated that more than 18.3 million of the 20.14 million Piggyback Options have already been exercised, generating approximately $22.88 million to date.

Shares in Racura Oncology traded at AUD 2.53 on 28 May 2026, declining 5.95% during the session. Over the past 12 months, however, the stock has risen approximately 82%, reflecting ongoing investor interest in the company’s oncology-focused clinical programs.

The company indicated that full conversion of all Piggyback Options would result in total proceeds of approximately $25.2 million, further strengthening its funding position as multiple clinical programs continue to advance.

Racura is a clinical-stage biopharmaceutical company focused on oncology therapies, with development programs targeting acute myeloid leukaemia (AML), lung cancer and anthracycline cardioprotection.

Underwriting Agreement Covers Remaining Options

According to the company, the underwriting agreement covers up to 1,838,524 Piggyback Options that remained unexercised at the time the agreement was executed.

Under the arrangement, the underwriter has agreed to subscribe for, or procure subscriptions for, ordinary shares equivalent to any unexercised options remaining at expiry.

The subscription price under the agreement is AUD 1.25 per share.

Racura stated that the maximum number of shares that may be issued under the underwriting arrangement is 1,838,524 shares, which would raise up to approximately $2.3 million before costs.

The company also noted that additional option conversions could still occur before the expiry date, potentially reducing the number of shares required under the underwriting arrangement.

Importantly, Racura confirmed that the underwriter is not a related party of the company.

The shares issued under the underwriting agreement are expected to be issued in accordance with ASX Listing Rule 7.2 Exception 10, meaning the issue will not affect the company’s Placement capacity under ASX Listing Rule 7.1 and will not require shareholder approval.

Clinical Programs Remain Central Funding Focus

Racura stated that funds raised through the underwriting arrangement and option exercises are expected to support several ongoing clinical programs.

The company said proceeds will be directed toward development activities involving AML, lung cancer and anthracycline cardioprotection programs, alongside general Working Capital requirements.

The company’s lead asset is RC220, a proprietary formulation of (E,E)-bisantrene.

According to Racura, the therapy is being advanced across several oncology indications through multiple clinical-stage programs.

Its clinical pipeline currently includes a Phase 3 program targeting acute myeloid leukaemia, a Phase 1a/b study involving mutant epidermal growth Factor receptor non-small cell lung cancer (EGFRm NSCLC), and a Phase 1a/b program involving combination use with anthracycline doxorubicin.

Racura is also exploring applications involving cardioprotection and enhanced anticancer activity for solid tumour patients.

The company stated that the additional funding is expected to assist in progressing these clinical initiatives.

Majority of Options Already Exercised

One of the notable aspects of the announcement was the high level of existing option conversions already completed ahead of expiry.

Racura confirmed that 18,303,269 of the total 20,141,793 Piggyback Options had already been exercised as of the announcement date.

These exercised options generated proceeds of approximately $22.88 million for the company.

The remaining balance of 1,838,524 options represented the portion covered under the underwriting agreement.

Management noted that further conversions were still anticipated prior to the final expiry deadline.

The Piggyback Options are scheduled to expire at 5pm on 29 May 2026.

Option exercises can provide listed companies with a source of non-Debt funding, particularly where options are already held by existing shareholders and issued under earlier capital raising initiatives.

For biotechnology companies progressing clinical-stage Assets, access to funding remains a key component of development planning due to the capital-intensive nature of Clinical Trials and regulatory processes.

Underwriting Provided Without Additional Fees

Racura also highlighted that no underwriting fee, commission or other consideration is payable under the agreement.

The company stated that the underwriting support was provided by the same investor who previously contributed approximately $3.22 million of funding in December 2025 at a premium to the prevailing Market Price.

Management said the underwriting opportunity was offered in recognition of the investor’s earlier support, which assisted the company in advancing its HARNESS-1 clinical trial earlier than originally planned.

Executive Chair Pete Smith acknowledged the role played by shareholders in supporting the company’s clinical development activities.

He noted that many shareholders had exercised their options early in order to support Racura’s ongoing development programs.

The company also thanked shareholders involved in supporting the advancement of its lung cancer trial.

Racura Continues Advancing Oncology Pipeline

Racura describes itself as a Phase 3-stage clinical biopharmaceutical company focused on cancer therapeutics.

Its development strategy centres around RC220, a formulation of (E,E)-bisantrene, which the company states primarily functions through G4-DNA and RNA binding mechanisms.

According to Racura, this mechanism contributes to silencing MYC, a cancer growth regulator associated with multiple tumour types.

The company also stated that recent discoveries involving the compound have enabled intellectual property filings providing up to 20 years of Patent protection.

Racura has collaborated with several research institutions and organisations including Astex, Emory University, Purdue University, MD Anderson, Sheba City of Health, UNC School of Medicine, the University of Wollongong and the University of Newcastle.

Management indicated that the company is also exploring Partnership opportunities, licensing agreements and potential Merger and Acquisition pathways aimed at accelerating global access to RC220.

Underwriting Agreement Includes Standard Conditions

The announcement also included details regarding termination provisions attached to the underwriting agreement.

The underwriter retains the ability to terminate the agreement under certain conditions, including scenarios involving material adverse changes, market disruptions, regulatory issues, Insolvency events or significant litigation matters.

Additional termination events include substantial falls in the S&P/ASX 200 index, breaches of material agreements, changes to the company’s Capital Structure without consent and other specified corporate or regulatory developments.

Such provisions are commonly included within underwriting agreements associated with listed companies and Capital Markets transactions.

Racura noted that the underwriting agreement remains subject to these standard contractual conditions.

Funding Environment Remains Important for Biotech Companies

Access to capital continues to play a significant role for clinical-stage biotechnology companies, particularly those progressing multiple oncology studies simultaneously.

Clinical trials, regulatory submissions and Drug Development programs often require ongoing Investment over extended timeframes before potential commercialisation outcomes emerge.

For Racura, the significant level of option exercises already completed, combined with the underwriting arrangement for remaining options, may provide additional financial flexibility as the company progresses its development pipeline.

The company’s focus on AML, lung cancer and cardioprotection also places it within therapeutic areas that continue attracting industry and investor interest globally.

What This Means for Investors

Racura Oncology’s latest announcement provides additional visibility around the company’s funding position ahead of the expiry of its Piggyback Options.

With more than 18.3 million options already exercised and the remaining balance fully underwritten, the company has outlined a pathway toward potentially securing approximately $25.2 million in total proceeds from the options program.

The additional capital is expected to support Racura’s clinical development programs involving AML, lung cancer and anthracycline cardioprotection, while also strengthening working capital.

The absence of underwriting fees and the support from an existing investor may also be viewed positively by some investors monitoring the company’s funding strategy.

Attention is now likely to shift toward the final expiry outcome of the Piggyback Options and continued progress across Racura’s clinical pipeline.